Skip to main content

ORIGINAL RESEARCH article

Front. Oncol.
Sec. Breast Cancer
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1437677
This article is part of the Research Topic The Exciting Opportunities and Challenges for Targeting “HER2 low” Breast Cancers and Beyond View all 8 articles

Higher baseline platelet and preoperative platelets to lymphocytes ratio was associated with a higher incidence of axillary node pathologic complete response after neoadjuvant chemotherapy in HER2-low breast cancer: A Retrospective Cohort Study

Provisionally accepted
Shuai Yang Shuai Yang 1*Guanying Liang Guanying Liang 2*Junyi Sun Junyi Sun 3*Lingbing Yang Yang Lingbing Yang Yang 1*Zitong Fu Fu Zitong Fu Fu 1*Wantong Sun Wantong Sun 1*Bo Wei Bo Wei 1*Qin Wang Qin Wang 1*Shouping Xu Shouping Xu 1*
  • 1 Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China
  • 2 Department of Pathology, Harbin Medical University Cancer Hospital, Harbin, China
  • 3 Central South University, Department of Urology, Xiangyang Central Hospital, Xiangyang, China

The final, formatted version of the article will be published soon.

    HER2 expression has a central role in breast cancer carcinogenesis and is associated with poor prognosis. Lately, identification of HER2-low breast cancer has been proposed to select patients for novel HER2-directed chemotherapy and includes cancers with immunohistochemistry (IHC) 1+or 2+with negative fluorescence in situ hybridization (FISH), encompassing approximately 55-60% of all breast carcinomas.Neoadjuvant chemotherapy(NAC) is an important therapeutic modality for HER2-low breast cancer (BC). Immune inflammatory biomarkers have been reportedly linked to the prognosis of some different breast cancer types, with varying results. In this study, we investigated the possible predictive roles of blood-based markers and clinicopathologic features in axillary pathologically complete response (pCR) after neoadjuvant treatment (NAT) in HER2-low BC.Cancer Hospital from January 2012 to December 2018 were included. Relevant clinical and pathological characteristics were included, and baseline and preoperative complete blood cell counts were evaluated to calculate four systemic immune-inflammatory markers: neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), and systemic immune-inflammation index (SII).The optimal cutoff values for these markers were determined using ROC curves and patients were classified into high-value and low-value groups based on these cutoff values. Univariate and multivariate logistic regression analyses were conducted to analyze factors influencing axillary pCR. The factors with independent predictive value were used to construct a forest map.A total of 998 patients were included in the study. 35.6% (355 of 998) of patients achieved axillary pCR after NAC. The result of multivariate logistic regression analysis showed that Estrogen receptor (ER) (OR=2.18; 95% CI 1.43-3.32; P<0.001),pathology type (OR=0.51; 95% CI 0.40-0.65; P<0.001),baseline platelet (OR=1.45; 95% CI 1.02-2.05; P=0.037),preoperative PLR (OR=1.63; 95% CI 1.01-2.64; P=0.046) were significant independent predictors of ypN0.The forest map for predicting axillary pCR incorporates four variables, including ER, pathology type, platelet,platelet-to-lymphocyte ratio (PLR). In patients treated with NAC, a higher baseline platelet and a higher preoperative PLR was associated with a higher incidence of axillary pCR.

    Keywords: breast cancer, HER2-low, Axillary node, Neoadjuvant chemotherapy, Pathologic complete response

    Received: 24 May 2024; Accepted: 20 Jan 2025.

    Copyright: © 2025 Yang, Liang, Sun, Yang, Fu, Sun, Wei, Wang and Xu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Shuai Yang, Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China
    Guanying Liang, Department of Pathology, Harbin Medical University Cancer Hospital, Harbin, China
    Junyi Sun, Central South University, Department of Urology, Xiangyang Central Hospital, Xiangyang, China
    Lingbing Yang Yang, Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China
    Zitong Fu Fu, Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China
    Wantong Sun, Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China
    Bo Wei, Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China
    Qin Wang, Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China
    Shouping Xu, Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.